Literature DB >> 11736950

Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study.

R Martino1, M D Caballero, C Canals, J A Simón, C Solano, A Urbano-Ispízua, J Bargay, C Rayón, A Léon, J Sarrá, J Odriozola, J G Conde, J Sierra, J San Miguel.   

Abstract

Reduced-intensity conditioning (RIC) regimens for allogeneic haematopoietic stem cell transplantation (SCT) have been shown to lead to engraftment of donor stem cells without the severe extra-haematological toxicities of traditional myeloablative transplants. Between December 1998 and December 2000, 76 patients underwent a RIC peripheral blood SCT in a prospective multicentre study. The median age was 53 years, and 57 patients were beyond the early phase of their disease. The conditioning regimens consisted of fludarabine (150 mg/m2) plus melphalan (140 mg/m2) or busulphan (10 mg/kg). Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporin A plus short-course methotrexate. The preparative regimens were well tolerated. All patients experienced severe pancytopenia, but haematological recovery was prompt in all but two cases (early deaths). The 100-d probability of developing grade II-IV acute GVHD was 32% (10% grade III-IV), and the 1-year probability of developing chronic extensive GVHD was 43%. Early complete donor chimaerism was observed in 52/68 patients, and 16 evaluable patients were in complete chimaerism 1 year post transplant. With a median follow-up of 283 d (355 in 48 survivors), the 1-year probability of transplant-related mortality was 20%, and the 1-year overall and progression-free survivals were 60% and 55% respectively. In conclusion, RIC regimens lead to low early toxicity after allografting, with stable donor haematopoietic engraftment, with an apparent low risk of acute GVHD. Chronic GVHD, however, develops in a significant proportion of patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11736950     DOI: 10.1046/j.1365-2141.2001.03153.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

1.  Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies.

Authors:  Joseph Rosenthal; Jeffrey Wong; Anthony Stein; Dajun Qian; Debbie Hitt; Hossameldin Naeem; Andrew Dagis; Sandra H Thomas; Stephen Forman
Journal:  Blood       Date:  2010-09-28       Impact factor: 22.113

2.  Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors.

Authors:  Kyle Jensen; L'Aurelle A Johnson; Pamala A Jacobson; Sonja Kachler; Mark N Kirstein; Jatinder Lamba; Karl-Norbert Klotz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-01-17       Impact factor: 3.000

3.  Efficacy of aprepitant in preventing nausea and vomiting due to high-dose melphalan-based conditioning for allogeneic hematopoietic stem cell transplantation.

Authors:  Masatoshi Sakurai; Takehiko Mori; Jun Kato; Yuya Koda; Taku Kikuchi; Sumiko Kohashi; Masuho Saburi; Takaaki Toyama; Yoshinobu Aisa; Tomonori Nakazato; Noriko Beppu; Soichiro Tsuda; Naoyuki Shigematsu; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2014-03-12       Impact factor: 2.490

4.  The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.

Authors:  Jose Antonio Perez-Simón; Rodrigo Martino; Rocío Parody; Mónica Cabrero; Lucía Lopez-Corral; David Valcarcel; Carmen Martinez; Carlos Solano; Lourdes Vazquez; Francisco J Márquez-Malaver; Jordi Sierra; Dolores Caballero
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

5.  Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Johan Törlén; Olle Ringdén; Jennifer Le Rademacher; Minoo Batiwalla; Junfang Chen; Tom Erkers; Vincent Ho; Partow Kebriaei; Carolyn Keever-Taylor; Tamila Kindwall-Keller; Hillard M Lazarus; Mary J Laughlin; Michael Lill; Tracey O'Brien; Miguel-Angel Perales; Vanderson Rocha; Bipin N Savani; David Szwajcer; David Valcarcel; Mary Eapen
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-02       Impact factor: 5.742

6.  Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors.

Authors:  A A Langston; J M Prichard; S Muppidi; A Nooka; M J Lechowicz; S Lonial; R Sinha; M Graiser; J L Kaufman; H J Khoury; C R Flowers; E K Waller
Journal:  Bone Marrow Transplant       Date:  2013-10-28       Impact factor: 5.483

7.  Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation.

Authors:  E Peres; J E Levine; Y A Khaled; R B Ibrahim; T M Braun; O I Krijanovski; S Mineishi; M H Abidi
Journal:  Bone Marrow Transplant       Date:  2009-05-25       Impact factor: 5.483

8.  Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials.

Authors:  José Luis Piñana; Rodrigo Martino; Jorge Gayoso; Anna Sureda; Javier de la Serna; Jose Luis Díez-Martín; Lourdes Vazquez; Reyes Arranz; José Francisco Tomás; Antonia Sampol; Carlos Solano; Julio Delgado; Jorge Sierra; Dolores Caballero
Journal:  Haematologica       Date:  2010-01-27       Impact factor: 9.941

9.  Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: success, disappointment, and new opportunities.

Authors:  Matthew D Blunt; Stephen G Ward
Journal:  Front Immunol       Date:  2012-08-02       Impact factor: 7.561

10.  Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation.

Authors:  Liana Nikolaenko; Saurabh Chhabra; Noa Biran; Arnab Chowdhury; Parameswaran N Hari; Amrita Krishnan; Joshua Richter
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.